Labcorp

Labcorp Holdings Inc., operating under the brand name Labcorp, is a global leader in innovative laboratory services and life sciences solutions headquartered in Burlington, North Carolina. Since its origins in 1969, Labcorp has grown to become one of the largest clinical laboratory networks in the world, with operations spanning over 100 countries and nearly 70,000 employees dedicated to improving health and improving lives.

The company provides comprehensive laboratory services used for diagnosis, healthcare decisions, drug development, and clinical research. Labcorp operates through two primary business segments: Diagnostics Laboratories and Biopharma Laboratory Services. The Diagnostics segment offers a vast menu of routine and specialty testing services, including blood chemistry analyses, urinalyses, thyroid tests, oncology testing, HIV genotyping, DNA testing, environmental testing, toxicology, and wellness services. The Biopharma segment provides crucial support to pharmaceutical companies and researchers, having supported more than 75% of new drugs and therapeutic products approved by the FDA in 2024.

In 2024, Labcorp demonstrated strong financial performance with revenues of $13.01 billion, representing a 6.97% increase from 2023. The company completed 10 strategic acquisitions totaling approximately $839 million, focusing on high-growth areas including oncology, neurology, and rare diseases. Notable acquisitions included select assets from Invitae, BioReference Health's laboratory testing business for $237.5 million, and outreach laboratory services from Community Health Systems for $194 million. These strategic moves strengthened Labcorp's position as a trusted partner to hospitals, health systems, and regional laboratories.

Labcorp has been at the forefront of diagnostic innovation, particularly during the COVID-19 pandemic when it developed the first at-home collection test and processed up to 165,000 tests per day in July 2020. The company continues to expand its test menu with cutting-edge biomarkers for early detection of conditions like Alzheimer's disease, including pTau217 and GFAP blood-based tests. In early 2025, Labcorp introduced Labcorp Plasma Complete, a crucial liquid biopsy tool that provides a less invasive diagnostic approach for cancer treatment decisions. The company also launched innovative solutions like Labcorp Global Trial Connect to accelerate clinical trials and expanded Labcorp OnDemand with consumer-initiated tests.

On May 17, 2024, Labcorp implemented a new holding company structure, with Labcorp Holdings Inc. replacing Laboratory Corporation of America Holdings as the publicly-traded entity. This reorganization positions the company for continued growth and innovation in the rapidly evolving healthcare landscape. With a strong commitment to diversity and inclusion, comprehensive employee benefits, and a mission-driven culture focused on improving health outcomes globally, Labcorp remains a cornerstone of modern healthcare infrastructure and pharmaceutical development.